Steve Inskeep and his brother, Bruce Inskeep, discuss tips on how to safely make a deep-fried turkey and chat about their family's celebrated holiday traditions.

Caribou plans a pivotal Phase 3 randomized trial evaluating approximately 250 patients in second-line large B-cell lymphoma. The FDA granted vispa-cel Regenerative Medicine Advanced Therapy, Orphan ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...

The US FDA has approved a subcutaneous version of Roche (RHHBY)-owned Genentech's follicular lymphoma treatment, Lunsumio ...

Given the vomiting and diarrhea, the biggest risk with norovirus is dehydration, which can turn a short-term illness into a ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

Various factors determine the best time to take your blood sugar medications, including how the medication works and its side effects.

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute –– Availability of Lunsumio VELO allows ...